Relieving eye-surface discomfort in glaucoma patients using multiple eye drops
Treatment of Ocular Discomfort in Glaucoma Patients Using Multiple Topical Medications
This will try Xiidra eye drops to relieve ocular surface discomfort in people with glaucoma who are using one or more topical glaucoma medications.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 75 (estimated) |
| Sex | All |
| Sponsor | University of California, Los Angeles Academic / other |
| Locations | 1 site (Fountain Valley, California) |
| Trial ID | NCT04354545 on ClinicalTrials.gov |
What this trial studies
This observational project follows glaucoma patients who are prescribed Xiidra (lifitegrast 5%) as part of routine care to address ocular surface discomfort related in part to topical glaucoma medications. Participants are adults already using one or more topical glaucoma antihypertensives and reporting symptoms of ocular surface discomfort, while patients with recent ocular surgery or current topical cyclosporine or steroid use are excluded. Researchers will document symptom changes and tolerability after Xiidra prescription without altering the treating clinician's plan. The work is conducted at Doheny Eye Center UCLA in Fountain Valley, California, with treatment provided as standard of care.
Who should consider this trial
Good fit: Ideal candidates are people with glaucoma who are using at least one topical glaucoma eye drop, report ocular surface discomfort, and whose clinician plans to prescribe Xiidra as standard care.
Not a fit: Patients with a history of glaucoma filtration or ocular surface surgery, those who had incisional ocular surgery in the past six months, or those currently using topical cyclosporine or steroids are unlikely to benefit from this observational evaluation.
Why it matters
Potential benefit: If successful, this could reduce eye-surface discomfort and make glaucoma medication use more comfortable for affected patients.
How similar studies have performed: Lifitegrast (Xiidra) is FDA-approved and has shown benefit for dry eye disease in prior studies, but its specific effects in glaucoma patients on multiple topical medications have been less well studied.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Currently using one or more topical glaucoma antihypertensives * Self-described symptoms of ocular surface discomfort * Xiidra is being prescribed as part of the subject's standard care Exclusion Criteria: * History of glaucoma filtration surgery, history of ocular surface surgery (pterygium, conjunctivoplasty, etc.), * current use of topical cyclosporine * current use of topical steroids * incisional ocular surgery within 6 months
Where this trial is running
Fountain Valley, California
- Doheny Eye Center UCLA — Fountain Valley, California, United States (Recruiting)
Study contacts
- Study coordinator: Benjamin B Bert, MD
- Email: BBert@mednet.ucla.edu
- Phone: 626-817-4701
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.